Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

30-Day Readmission After S. aureus Bacteremia

Clin Infect Dis; ePub 2019 Feb 11; Inagaki, et al

In a retrospective analysis using the 2014 Nationwide Readmissions Database, 30-day readmissions after Staphylococcus aureus (S. aureus) bacteremia was found to be common and costly in the US. Researchers identified MSSA and MRSA bacteremia among patients aged ≥18 years. 30-day readmission, mortality, length of stay (LOS), and costs were assessed. They found:

  • Of 92,089 patients with S. aureus bacteremia, 48.5% had MRSA bacteremia.
  • 30-day readmission rate was 22% overall with no difference between MRSA and MSSA.
  • However, MRSA bacteremia had more readmission for bacteremia recurrence , increased mortality, and longer hospitalization.
  • The cost of readmission was $12,425/case overall, and $19,186 in those with bacteremia recurrence.


Inagaki K, Lucar J, Blackshear C, Hobbs CV. Methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia—Nationwide estimates of 30-day readmission, in-hospital mortality, length of stay, and cost in the US. [Published online ahead of print February 11, 2019]. Clin Infect Dis. doi:10.1093/cid/ciz123.